News ArchivesRead News
Stem cells may aid Parkinson's treatment
Tuesday January 29, 2013
www.sfgate.com - There is much excitement in the medical profession about how stem-cell-based therapies could someday affect how Parkinson's disease is treated.
Parkinson's disease is a neurological disorder caused by the dying off of a certain type of brain cells. These cells are located in the midbrain of the brainstem in an area called the substantia nigra.
They are responsible for making a neurotransmitter called dopamine. Without the effect of dopamine, a patient can develop problems with initiating and coordinating movement, along with other symptoms characteristic of Parkinson's disease.
Current drug treatments of Parkinson's disease work by increasing dopamine levels or activity at dopamine receptors. But Parkinson's experts are hopeful that stem-cell therapies will soon provide new treatment options or even a cure for the disease by reproducing the lost dopamine-making cells.
The four cardinal symptoms of Parkinson's disease are tremor (shaking of the hand or other parts of the body), bradykinesia (slowing of movement), postural instability (problems with balance) and rigidity (muscle stiffness).
Other characteristic symptoms include loss of facial expression, reduction in volume of the voice (called hypophonia), small handwriting (called micrographia), drooling, trouble swallowing, difficulty initiating movement (called freezing), stooped posture and a shuffling gait.
There are also "non-motor" symptoms, which refer to problems not related to movement, including sleep disturbances, fatigue and pain.
As the disease progresses, worsening mobility occurs, and death may result from pneumonia from aspiration or pulmonary embolism due to immobility. Falls are also common as the disease progresses, which can lead to injury. However, patients can live for decades after diagnosis, meaning the condition may not necessarily lead to a reduction in life span.
The gold-standard pharmacologic treatment for Parkinson's disease is a medication called Sinemet, which has been around since the late 1960s. It contains levodopa, which is the precursor of dopamine.
Because levodopa is converted to dopamine in the central nervous system, Parkinson's symptoms improve with this medication because it is replacing exactly what is missing in the disorder.
In fact, demonstrating a clear beneficial response from Sinemet has been the traditional way to confirm the diagnosis of Parkinson's disease.
However, the effect of pharmacologic treatment tends to diminish as the disease progresses, and patients also become more sensitive to treatment-related side effects over time.
Consequently, complex, multidrug regimens are often required to maintain adequate symptom control with good tolerability in advanced stages of the disease.
The excitement surrounding stem-cell-based therapies is that the stem cells can be induced to grow into a particular type of mature cell, including the dopamine-producing cells that are lost in Parkinson's disease. Stem cells can be embryonic or they can be induced from adult cells.
The efficacy of stem-cell treatments has been variable in animal models, and there have been safety concerns, including the risk of tumor development and rejection of transplanted cells.
Future research will be required to determine the effectiveness and safety of these various treatments, but there is hope that the way Parkinson's disease and possibly other neurodegenerative disorders are treated may be on the verge of dramatic change.
Dr. Mark Saleh is a neurologist at the Sutter Pacific Medical Foundation and the director of General Neuroconsultative and Referral Services at California Pacific Medical Center.
Recent NewsOct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show